PRAX - NASDAQ
Praxis Precision Medicines, Inc.
$278.93
+3.3%Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal imbalance. Its lead product candidates include PRAX-114, an extrasynaptic-preferring GABAA receptor positive allosteric modulator that is in Phase IIa clinical trial for the treatment of major depressive disorder and perimenopausal depression; and PRAX-944, a selective small molecule inhibitor of T-type calcium channels, which is in Phase IIa clinical trial for the treatment of essential tremor. The company is also developing PRAX-562, a persistent sodium current blocker that is in Phase I clinical trial to treat severe pediatric epilepsy and adult cephalgia; PRAX-222, an antisense oligonucleotide (ASO) for patients with gain-of-function (GOF) SCN2A epilepsy; and KCNT1 program for the treatment of KCNT1 GOF epilepsy. It has a cooperation and license agreement with RogCon Inc.; a license agreement with Purdue Neuroscience Company; a research collaboration, option, and license agreement with Ionis Pharmaceuticals, Inc.; and collaboration with The Florey Institute to develop three novel ASOs. The company was incorporated in 2015 and is based in Boston, Massachusetts.
At a Glance
Live Snapshotprax
Property, Plant, and Equipment (Net)
Last Annual Value
239.00K
3-Year CAGR
-60%
5-Year CAGR
-22%
10-Year CAGR
9%
Praxis Precision Medicines, Inc. Competitors Analysis of Property, Plant, and Equipment (Net)
| Company | Property, Plant, and Equipment (Net) | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
Praxis Precision Medicines, Inc. NASDAQ:PRAX | 239.00K | -55.2% | -45.3% | N/A | |
 Crinetics Pharmaceuticals, Inc. NASDAQ:CRNX | 54.79M | -1.6% | 63.3% | 73.3% | |
 Ligand Pharmaceuticals Incorporated NASDAQ:LGND | 10.79M | -24.5% | -19.8% | 19.5% | |
 Kymera Therapeutics, Inc. NASDAQ:KYMR | 85.53M | -5.4% | 32.0% | N/A | |
 Akero Therapeutics, Inc. NASDAQ:AKRO | 755.00K | -9.7% | -13.4% | N/A | |
 Viking Therapeutics, Inc. NASDAQ:VKTX | 85.00K | -57.7% | 27.7% | N/A | |
 ACADIA Pharmaceuticals Inc. NASDAQ:ACAD | 54.87M | -1.0% | -3.7% | 33.4% | |
 Immunovant, Inc. NASDAQ:IMVT | 515.00K | -30.1% | -31.8% | N/A | |
 Soleno Therapeutics, Inc. NASDAQ:SLNO | 2.38M | 78.3% | 39.2% | 36.9% |
Praxis Precision Medicines, Inc. Fair Value Envelope
Related Guides
Continue your PRAX research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.